Trial record 3 of 105 for:    St. Joseph Hospital AND Orange AND CA | Open Studies

Single Fraction Intraoperative Radiotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by St. Joseph Hospital of Orange
Sponsor:
Information provided by (Responsible Party):
St. Joseph Hospital of Orange
ClinicalTrials.gov Identifier:
NCT01688388
First received: September 12, 2012
Last updated: September 20, 2012
Last verified: September 2012
  Purpose

This clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer. This single fraction intraoperative radiotherapy with electrons will study the toxicity, local control and cosmetic outcome.


Condition Intervention Phase
Invasive Ductal and Invasive Lobular Breast Carcinoma
Stage 0 Breast Carcinoma
Stage I Breast Carcinoma
Stage II Breast Carcinoma
Procedure: Intraoperative Radiotherapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial

Resource links provided by NLM:


Further study details as provided by St. Joseph Hospital of Orange:

Primary Outcome Measures:
  • Toxicity Assessment [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

    Assessment of acute toxicity of breast irradiation according to CTC-toxicity Scoring - system:

    • End of initial surgical phase: Week 1, 4
    • First Follow-up investigation: Month 2 Assessment of late toxicity according to NSABP scoring-systems at 6, 12, 24, 36, 48, and 60 months


Secondary Outcome Measures:
  • Cosmetic Evaluation [ Time Frame: 5 years ] [ Designated as safety issue: No ]

    Assessment of cosmetic outcome according to 5-point scoring system

    • Week 1, 2; Month 2, 6, 12, 24, 36, 48, 60
    • At yearly follow-up (photodocumentation in standardized positions) for 5 years

  • Recurrence Assessment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Recurrence is assessed at month 6, 12, 24, 36, 48, 60


Estimated Enrollment: 200
Study Start Date: February 2012
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IORT Arm
Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
Procedure: Intraoperative Radiotherapy
Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
Other Name: IORT

Detailed Description:

For patients with certain types of breast cancer, one standard treatment is breast conserving surgery or lumpectomy (surgery to remove abnormal tissue or cancer from the breast and a small amount of normal tissue around it) followed by breast radiation. The radiation treatment in this situation usually lasts 3 to 5 1/2 weeks followed by 5-8 daily localized irradiation (or boost) treatments at the site where the lump was removed. During this study, the single dose of electron irradiation given at the surgical site during the operation will replace the radiation given after surgery.

  Eligibility

Ages Eligible for Study:   41 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological proven invasive breast carcinoma ductal, lobular and/or Ductal Carcinoma in situ
  • Age > 40 years
  • Karnofsky performance status > 70%
  • Tumor. Single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm
  • Nodal Status: preoperatively N0
  • Clear surgical margins: R0
  • All grades G1 - G3
  • Any hormonal receptor and HER-2 status
  • Informed consent

Exclusion Criteria:

  • Gender: male
  • Tumor size: more than 2.5 cm
  • Nodal status greater than or equal to N1 pathologically
  • Multicentricity
  • Previous radiotherapy to the involved breast
  • Karnofsky Index < 70%
  • Mixed connective tissue diseases e.g. rheumatoid poly arthritis, thromboangitis obliterans, systemic lupus
  • Distant metastases
  • Pregnancy in woman of child bearing age
  • Unable to provide written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01688388

Contacts
Contact: Heather Weiss, BS 714-734-6220 ext 40838 Heather.Weiss@stjoe.org
Contact: Carmen Moronez

Locations
United States, California
St. Joseph Hospital of Orange Recruiting
Orange, California, United States, 92868
Contact: Heather Weiss, BS    714-734-6220 ext 40838    Heather.Weiss@stjoe.org   
Contact: Carmen Moronez         
Principal Investigator: Afshin Forouzannia, M.D.         
Sponsors and Collaborators
St. Joseph Hospital of Orange
Investigators
Study Chair: Lawrence Wagman, M.D. St. Joseph Hospital of Orange
  More Information

No publications provided

Responsible Party: St. Joseph Hospital of Orange
ClinicalTrials.gov Identifier: NCT01688388     History of Changes
Other Study ID Numbers: 12-001 Single Fraction IORT
Study First Received: September 12, 2012
Last Updated: September 20, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by St. Joseph Hospital of Orange:
Breast Cancer
Carcinoma
Radiotherapy
Intraoperative Radiotherapy
IORT

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Ductal, Lobular, and Medullary
Carcinoma
Carcinoma in Situ
Carcinoma, Lobular
Breast Diseases
Skin Diseases
Adenocarcinoma

ClinicalTrials.gov processed this record on August 21, 2014